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Muscle Microvascular Dysfunction in Central Obesity Is
Related to Muscle Insulin Insensitivity but Is Not
Reversed by High-Dose Statin Treatment
Geraldine F. Clough,1 Magdalena Turzyniecka,1 Lara Walter,1 Andrew J. Krentz,1 Sarah H. Wild,2
Andrew J. Chipperfield,3 John Gamble,4 and Christopher D. Byrne1
OBJECTIVE—To test the hypotheses that decreased insulin-
mediated glucose disposal in muscle is associated with a reduced
muscle microvascular exchange capacity (Kf) and that 6 months
of high-dose statin therapy would improve microvascular func-
tion in people with central obesity.
RESEARCH DESIGN AND METHODS—We assessed skeletal
muscle microvascular function, visceral fat mass, physical activ-
ity levels, fitness, and insulin sensitivity in skeletal muscle in 22
female and 17 male volunteers with central obesity whose age
(mean  SD) was 51  9 years. We tested the effect of
atorvastatin (40 mg daily) on muscle microvascular function in a
randomized, double-blind, placebo-controlled trial lasting 6
months.
RESULTS—Kf was negatively associated with a measure of
glycemia (A1C; r  0.44, P  0.006) and positively associated
with insulin sensitivity (the ratio of insulin-stimulated glucose
effectiveness, or M value, to the mean insulin concentration, or I
value; r  0.39, P  0.02). In regression modeling, A1C, visceral
fat mass, and M:I explained 38% of the variance in Kf (in a linear
regression model with Kf as the outcome [R
2 0.38, P 0.005]).
M:I was associated with Kf independently of visceral fat mass (B
coefficient 3.13 [95% CI 0.22–6.02], P  0.036). Although 6
months’ treatment with atorvastatin decreased LDL cholesterol
by 51% (P 0.001) and plasma high-sensitivity C-reactive protein
by 75% (P  0.02), microvascular function was unchanged.
CONCLUSIONS—Decreased insulin-mediated glucose uptake
in skeletal muscle is associated with impaired muscle microvas-
cular exchange capacity (Kf), independently of visceral fat mass.
Muscle microvascular function is not improved by 6 months of
high-dose statin treatment, despite marked statin-mediated im-
provements in lipid metabolism and decreased inflammation.
Diabetes 58:1185–1191, 2009
Microvascular dysfunction is a cardinal long-term complication of type 2 diabetes. Re-ported microvascular defects in type 2diabetes include impaired endothelium-
dependent vasodilatation, reduced substrate delivery, and
lower capillary density in insulin-sensitive tissues (1).
Increased glycation of erythrocyte membrane proteins
causing rigidity may result in an increased resistance to
travel through the microcirculation (2), while concomitant
alterations of the endothelial cell surface glycocalyx may
modulate vascular permeability and exchange surface area
(3). Obesity is the most important modifiable risk factor
for the development of type 2 diabetes. Microvascular
dysfunction has also been reported in obese subjects in
the absence of diabetes, but it remains unclear which
component(s) of obesity-linked pathophysiology contrib-
utes to microvascular dysfunction (1,4–6). Increased body
fat mass is associated with molecular changes that con-
tribute to altered vasodilatory responses, oxidative stress,
abnormalities of vasoconstriction, and altered platelet
adhesion; all of these defects could potentially influence
solute delivery via the microvasculature (5). Insulin in-
creases blood flow and microvascular perfusion in skin
(7,8) and skeletal muscle (9,10), and impairment of insulin-
induced microvascular dilator responses in skeletal mus-
cle in animal models of insulin resistance, even at basal
insulin concentrations, is believed to be a key factor in
reduced glucose uptake (4,11). Thus, microvascular dys-
function might contribute to obesity-associated insulin
resistance. Studies in insulin-resistant states in humans,
such as obesity with or without the presence of type 2
diabetes (12), have shown impaired microvascular func-
tion where both insulin-mediated muscle microvascular
perfusion and glucose uptake are reduced (5,13). The
attenuation of insulin-stimulated muscle microvascular
perfusion recruitment in obese humans is reminiscent of
that reported in obese Zucker rats (6), being suggestive of
common mechanistic pathways, including increased pro-
duction of reactive oxygen species and reduced nitric
oxide (NO) availability.
Based on results in animal models, it has been proposed
that insulin acts to dilate the arterioles governing flow
through capillary beds (14), thereby increasing substrate
delivery (15). This occurs independently of, and appears to
precede, increases in total blood flow and glucose disposal
(14) resulting from dilatation of upstream arteriolar ves-
sels (16). Entangled with this hypothesis is the concept of
insulin-mediated redistribution of blood flow through the
preferential perfusion of so-called nutritive vessels at the
expense of nonnutritive routes (17). In healthy humans,
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many, but not all, experimental studies have shown insulin
to have dose- and time-dependent effects, increasing blood
flow in a manner that parallels glucose disposal (18).
However, whether the capacity of insulin to increase the
number of patent capillaries (capillary recruitment) is
impaired in insulin-resistant states, such as obesity, re-
mains uncertain (19–21).
It is well accepted that treatment with statins decreases
risk of macrovascular disease and that statins have pleio-
tropic actions. Statins are also effective treatments for
targeting vascular risk in people with features of the
metabolic syndrome (22). However, the extent to which
statin therapy has beneficial effects on the microvascula-
ture has been little studied and remains unclear. Within
the macrovasculature, statins have been shown to improve
endothelial function and attenuate endothelial dysfunction
in the presence of atherosclerotic risk factors through
upregulation of endothelial NO synthase and the increased
production of NO, and such an effect has been shown to
occur after 6 months of therapy (rev. in 23). However, the
potential for statins to modulate endothelial function in
smaller vessels has yet to be elucidated.
Although it is known that microvascular dysfunction
occurs in obesity, the nature of the relationship between
microvascular function in an insulin-sensitive tissue such
as skeletal muscle and insulin-mediated glucose disposal
in skeletal muscle is uncertain. The role of potential
confounders, such as fitness and physical activity levels, in
the relationship between skeletal muscle microvascular
function and insulin-mediated glucose disposal in skeletal
muscle have not been fully clarified. Moreover, it is not
certain whether statin therapy confers any benefit on
muscle microvascular function via hypothesized pleiotro-
pic actions independently of an effect on circulating LDL
cholesterol concentrations.
The aims of our study were to assess the relationship
between insulin-mediated glucose disposal and measures
of skeletal muscle microvascular function, including mi-
crovascular filtration capacity (Kf), a measure of microvas-
cular integrity (isovolumetric pressure [Pvi]), and resting
limb blood flow (Qa), and to test the effect of statins on
these factors in individuals with central obesity. We hy-
pothesized 1) that decreased insulin-mediated glucose
disposal in muscle is associated with a reduced muscle Kf
and 2) that 6 months’ intensive high-dose statin treatment
would reverse this microvascular dysfunction (potentially
via the pleiotrophic actions of statins on NO production).
We took care to assess potential confounders, such as
physical inactivity and cardiorespiratory fitness, that are
known to influence Kf (24).
RESEARCH DESIGN AND METHODS
The study was approved by the Southampton General Hospital research ethics
committee (LREC05/Q1704/38) and conducted in accordance with the Decla-
ration of Helsinki. All participants were unpaid volunteers and gave informed
written consent. White European subjects aged 18–75 years were invited to
participate in the study. Volunteers were eligible for the main study if they had
central obesity and at least one other feature of the metabolic syndrome as
assessed by International Diabetes Federation criteria (25). For ethical
reasons, subjects were only included in the study if estimated cardiovascular
risk was 20% over 10 years based on the equation derived from the
Framingham Heart Study because national guidelines indicate that people at
higher cardiovascular risk should receive statin treatment for primary preven-
tion of cardiovascular disease. Exclusion criteria were known diabetes; renal,
liver, or uncontrolled thyroid disease; uncontrolled hypertension (blood
pressure 160/100 mmHg); treatment with lipid-modifying drugs; antihyper-
tensive medication; corticosteroid therapy; or hormone replacement therapy.
For more information on the subjects and methods, please refer to the supple-
mental appendix, available online at http://dx.doi.org/10.2337/db08-1688.
After completing the baseline tests, subjects were randomized in a double-
blind placebo-controlled trial study design by an independent pharmacist to
either 40 mg atorvastatin daily or to matched placebo for 26 weeks. The
primary end point of the trial was a change in microvascular function.
Previously, Charles et al. (26) studied 12 individuals in a 14-week training
program during which lower limbs were trained for endurance exercise, and
these authors showed a 79% improvement in Kf (from 2.4  0.8 to 4.3  0.9,
P  0.05). Brown et al. (24), using electrical stimulation for 4 weeks in five
sedentary individuals (8 Hz, 3  20 min/day for 5 days per week), showed that
Kf increased 200%, from 3.38  0.38 to 6.68  0.62 (P  0.05). We estimated
that a sample size of n  40 subjects would give us 99% power at the 5%
significance level to detect a 1-SD increase in Kf and that, based on the
changes shown with exercise and electrical stimulation studies, such a
functional change would be physiologically relevant. Data are presented on 39
subjects because one person was unable to complete the study after suffering
side effects of the prescribed trial medication.
Body composition, fat mass, and lean body mass were measured using a
dual X-ray absorptiometry Delfia W 4500 instrument (coefficient of variation
0.68%; Hologic, Bedford, MA) using a standard visual method to divide images
into trunk, limb, and head. An abdominal magnetic resonance imaging scan
was undertaken to assess visceral fat (27–29). An oral glucose tolerance test
was performed with a 75-g glucose load with samples collected after 2 h.
The following tests were undertaken at baseline and at 26 weeks: micro-
vascular function was assessed using a Filtrass venous occlusion plethysmo-
graphic system using a passive inductive transducer with an accuracy of 5
m (Compumedics DWL, Singen, Germany). Filtration (Jv in ml  min
1  100
ml1) was measured from the slope of volume change in response to each
pressure step over the last 2 min of its application, to allow for completion of
vascular filling, and plotted against cuff pressure (Pcuff). The slope of this
relationship, at pressures above those giving rise to net filtration, is a measure
of microvascular filtration capacity (Kf) (30). Extrapolation of the relationship
to its intercept on the Pcuff axis gives the isovolumetric venous pressure (Pvi)
at which there is neither net filtration nor absorption (30,31). Muscle strength
was assessed by measurement of handgrip strength using a Jamar dynamom-
eter (Promedics, Blackburn, U.K.).
Hyperinsulinemic-euglycemic clamp. A hyperinsulinemic-euglycemic
clamp was undertaken to assess whole-body glucose uptake (insulin-stimu-
lated glucose effectiveness, or M value) during the steady state of the clamp
(final 30 min of the clamp), both at baseline and after intervention while
subjects were taking their trial medication (32).
Measurement of insulin sensitivity. Whole-body insulin sensitivity was
measured as glucose uptake during the steady state of the clamp with an
insulin infusion rate of 1.5 mU  kg1  min1. All individuals achieved
euglycemia during the clamp with glucose concentrations clamped at 5.0
mmol/l. Whole-body glucose uptake (M value) was defined as the glucose
infusion rate during the final 30 min of the test (in mg  kg1  min1) when
steady-state insulin concentrations had been achieved. The ratio of M to the
mean insulin concentration (I value) was used as an index of insulin
sensitivity. M:I values were estimated by dividing the M value by the I value
during the last 30 min of the clamp.
Cardiorespiratory fitness and physical activity energy expenditure.
Cardiorespiratory fitness measured in terms of maximal oxygen uptake
(VO2max) was determined using a treadmill test and Cortex Metalyzer, and
physical activity (physical activity energy expenditure and metabolic equiva-
lents) was assessed using an activity monitor (Armband Sensewear Pro2) (33).
Statistical analyses. All statistical analyses were performed using SPSS for
Windows version 16.0 (SPSS, Chicago, IL). Student’s t test comparisons were
undertaken to compare mean values of normally distributed data. Pearson
correlation coefficients are presented for univariate analyses of normally
distributed data. Where variables were not normally distributed, log transfor-
mation was undertaken to normalize the distribution. Multivariate linear
regression models were used to describe factors that were independently
associated with Kf as the dependent (outcome) variable. A P value of 0.05
was considered to be statistically significant for all analyses. Data are
expressed as the mean  SD and range unless otherwise stated. To test the
effect of statin on measures of microvascular function, we analyzed micro-
vascular function at the end of the trial, adjusting for randomization and
baseline microvascular measures by factorial ANOVA.
RESULTS
Table 1 shows the baseline characteristics of subjects
recruited to the study. The 39 healthy volunteers included
17 men and were aged 51  9 years. Of the study subjects,
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11 had two features, 18 had three features, 9 had four
features, and 1 had all five features of the metabolic
syndrome. Subjects were excluded if they had known
diabetes at recruitment. On baseline testing one subject
was found to have a fasting glucose of 7.4 mmol/l and
therefore analyses were undertaken both including and
excluding this person. Inclusion of data from this individ-
ual (who received no glucose-lowering medication during
the study) did not change or affect the results, and the data
are therefore presented for all 39 subjects who completed
the 6-month trial. For more information on the results of
this study, please refer to the supplementary material in
the online appendix.
Figure 1 shows baseline Kf, Qa, and Pvi measurements.
Mean values for Kf, Qa, and Pvi were 3.91  0.18  10
3
ml  min1  100 ml1  mmHg1, 4.01 0.48 ml  min1  100
ml1, and 20.5  1.1 mmHg, respectively. There was
considerable variability in all measures within the cohort
with an approximately threefold difference in Kf levels
between subjects.
We investigated the relationships between measures of
microvascular function (Kf, Qa, and Pvi), measures of
obesity and features of the metabolic syndrome, together
with measures of physical activity and fitness. Table 2
shows correlation coefficients describing the relationships
between Kf, age, features of the metabolic syndrome,
VO2max, physical activity energy expenditure, and meta-
bolic equivalents. Of the readily measurable features of the
metabolic syndrome (waist circumference, blood pres-
sure, glucose, HDL cholesterol, and triglyceride concen-
trations), Kf was statistically significantly associated with
waist circumference (r  0.36, P  0.025). There was a
borderline significant association with triglycerides (r 
0.30, P  0.07), and there were no significant associa-
tions between Kf and age, blood pressure, glucose, or HDL
cholesterol concentrations. Figure 2 shows the scatter
plots for the relationships between Kf and visceral fat,
A1C, and M:I. Kf was negatively associated with visceral
fat (r0.43, P 0.015) and A1C (r0.44, P 0.006).
Kf was also negatively associated with plasma high-sensi-
tivity C-reactive protein (hsCRP) and soluble intracellular
adhesion molecule (ICAM)-1 (both P  0.05). Kf was
positively associated with M:I (r  0.39, P  0.02). There
were no significant associations of note with Pvi. Resting
Qa was associated with respiratory exchange ratio (r 
0.52, P  0.002). Neither Pvi nor Qa were associated with
age (r  0.20, P  0.24, and r  0.12, P  0.94,
respectively).
Multiple regression modeling was undertaken to further
explore factors that were associated with Kf. In a regres-
sion model that included Kf as the outcome, 38% of the
variance in Kf was explained by A1C, M:I, and visceral fat
mass as the explanatory variables in the model (R2 0.38,
P 0.005). To determine whether the association between
M:I and Kf (observed in univariate analysis) (Table 2) was
independent of visceral fat, we undertook regression mod-
eling with Kf as the outcome variable and includedM:I and
visceral fat as explanatory variables. In this model,M:I and
visceral fat explained 30% of the variance in Kf (R
2  0.30,
P  0.008). M:I was associated with Kf independently of
visceral fat (B coefficient  3.13, 95% CI 0.22–6.02, P 
0.036), whereas visceral fat was not associated with Kf
independently of M:I (B coefficient  0.09, 95% CI 0.40
to 0.22, P  0.55). There was no effect of sex in our model.
Having observed associations with measures of insulin
sensitivity and microvascular function in muscle, we in-
vestigated whether a functional measure of muscle perfor-
mance (grip strength) was associated with measures of
microvascular function. Only Pvi was associated with grip
TABLE 1
Baseline characteristics of participants
Mean  SD Range
Age (years) 51.4 9.0 29.0–69.6
BMI (kg/m2) 32.1 4.6 26.0–47.9
Waist (cm) 105.3 12.9 86.5–151.0
Total fat (%) 35.6 7.4 21–48
Truncal fat (% of total) 52.2 5.6 43–64
Systolic blood pressure (mmHg) 133 14 93–155
Diastolic blood pressure (mmHg) 85 9 64–104
Cardiovascular disease risk
(% per 10 years)* 7.3 5.1 0–17.3
Total cholesterol (mmol/l) 5.7 1.1 3.2–9.3
LDL cholesterol (mmol/l) 3.7 0.9 1.7–7.0
HDL cholesterol (mmol/l) 1.45 0.36 0.92–2.45
Triglyceride (mmol/l) 1.4 0.6 0.4–2.7
Glucose (mmol/l) 5.2 0.7 4.0–7.4
A1C (%) 5.5 0.3 4.9–6.3
% fat estimated by DEXA. *Estimated using Framingham risk score.
FIG. 1. Baseline measurements of filtration capacity (Kf), resting limb
blood flow (Qa), and endothelial integrity (Pvi) from 39 individuals. All
values were derived using venous congestion plethysmography from
the raw data (see supplemental information in the online appendix).
Qa  resting (ml  100 ml1  min1); Kf   10
3 ml  min1  100 ml1 
mmHg1; Pvi  mmHg.
TABLE 2
Correlations between filtration capacity (Kf) and features of the
metabolic syndrome, abdominal obesity, fitness, and physical
activity
r P
Age (years) 0.02 0.89
Waist (cm) 0.36 0.025
Visceral fat (kg) 0.43 0.015
Subcutaneous fat (kg) 0.28 0.12
Systolic blood pressure (mmHg) 0.15 0.36
Diastolic blood pressure (mmHg) 0.08 0.63
Cardiovascular disease risk (% per 10
years) 0.15 0.38
HDL cholesterol (mmol/l) 0.13 0.43
Triglyceride (mmol/l) 0.30 0.07
Glucose (mmol/l) 0.05 0.77
A1C (%) 0.44 0.006
Steps (n) 0.35 0.04
Physical activity energy expenditure
(metabolic equivalents) 0.20 0.24
Vo2max (ml  min
1  kg1) 0.21 0.20
Glucose disposal (mg  kg1  min1 
mIU1  l1) 0.39 0.021
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strength {mean handgrip strength [(right	 left)/2]} and Pvi
(r0.55, P 0.001). We observed similar results for the
relationship between Pvi and left handgrip strength (r 
59, P  0.001) and right handgrip strength (r  0.51,
P  0.001).
We investigated the effect of 6 months of 40 mg/day of
atorvastatin treatment in the randomized placebo con-
trolled trial. In subjects in the placebo arm of the study
(n  20), mean baseline LDL cholesterol was 3.78  1.05
mmol/l, and it was 3.70  0.90 mmol/l at follow-up (P 
0.51). In contrast, in the treatment arm of the study (n 
19), LDL cholesterol fell from 3.53  0.81 mmol/l at
baseline to 1.73  0.71 mmol/l at follow-up (P  0.001).
Subjects in the placebo arm of the study had a mean
baseline triglyceride of 1.31  0.68 mmol/l, and triglycer-
ide was 1.19  0.61 mmol/l at follow-up (P  0.34). Mean
baseline fasting triglyceride concentration in the treatment
arm of the study was 1.41  0.62 mmol/l, compared with
1.00  0.58 mmol/l at follow-up (P  0.001). Median
baseline hsCRP in subjects in the placebo arm of the study
was 2.0 mg/l (95% CI 1.09–10.47) compared with 3.0 mg/l
(1.62–6.35) at follow-up (P 0.73). Statins reduced hsCRP
from a baseline value of 2.0 mg/l (95% CI 1.31–5.59) to 0.5
mg/l (0.35–4.65) at follow-up (P  0.02). The change in
LDL cholesterol concentration was positively correlated
with the change in hsCRP (r 0.27, P 0.002). In both the
placebo and treatment arms of the study, there was no
change in body fat, M:I, A1C, or ICAM-1 measurements
after 6 months of treatment (data not shown). Figure 3
shows Kf, Pvi, and Qa measurements before and after 6
months’ treatment with atorvastatin. There was no change
in Kf, Pvi, and Qa measurements with statin treatment,
adjusting for baseline measures, age, and sex (Kf: P 0.99;
Pvi: P  0.28; Qa: P  0.29).
DISCUSSION
Our results show that in adults with central obesity,
decreased insulin-mediated glucose uptake in skeletal
muscle is associated with impaired muscle Kf indepen-
dently of visceral fat mass. Our data demonstrate that the
association between Kf and insulin-mediated glucose dis-
posal is independent of visceral fat mass, with no con-
founding by physical inactivity or low fitness levels.
Despite a wealth of evidence showing that statins confer a
benefit in the macrovasculature, and despite a marked
statin effect on LDL cholesterol levels (lowered by 50%)
and hsCRP (decreased by 75%), our results clearly show
no effect of statin on measures of muscle microvascular
function.
In our study, insulin-mediated glucose disposal (M:I)
was positively associated with exchange capacity (Kf),
suggesting that the more insulin-sensitive individuals have
a greater exchange capacity, thereby facilitating muscle
nutrient delivery. Although the range of values of Kf
measured in our study group was considerable, they were
similar to those reported previously for similarly aged
individuals (26,34). The values of Kf are also within the
range reported for individuals with pre-diabetes or diabe-
tes without microvascular complications (35–38). We
failed to show any association between age and any of the
measures of microvascular function in our study. How-
ever, the mean age of our volunteers was 51.4 years with
an SD of only 9 years. Thus, it is plausible that in our
relatively small sample size of predominantly middle-aged
subjects, we have failed to detect true associations be-
tween aging and measures of microvascular function. It is
also possible that because we have not studied very aged
individuals, we have not detected any obesity-indepen-
dent, age-related change in microvascular function.
FIG. 2. Scatter plots for the relationships between Kf and visceral fat, A1C, and M:I from 39 individuals at baseline. Kf was negatively associated
with visceral fat (r  0.43, P  0.015) and A1C (r  0.44, P  0.006) and positively associated with M:I (r  0.39, P  0.02).
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Having shown associations between insulin-mediated
glucose uptake in skeletal muscle and Kf, we also explored
whether a functional measure of skeletal muscle perfor-
mance (grip strength) was associated with measures of
muscle microvascular function, since we have recently
shown in a large cohort study that decreased grip strength
was associated with metabolic syndrome (39) and type 2
diabetes (40). The mechanism underlying decreased hand-
grip strength in type 2 diabetes and metabolic syndrome is
uncertain, but, interestingly, our results show that one
measure of microvascular integrity (Pvi) was associated
with decreased grip strength. In other studies, increases in
Pvi have been associated with inflammatory disease (41),
but whether vascular inflammation within skeletal muscle
may contribute to loss of muscle strength in people with
type 2 diabetes has yet to be explored.
Our results showed a marked effect of atorvastatin to
decrease LDL cholesterol and CRP, but, in keeping with
previous work (42) testing the effects of 12 weeks’ treat-
ment with atorvastatin, we showed no effect of atorvasta-
tin on levels of inflammatory markers (e.g., ICAM-1, tumor
necrosis factor-
, interleukin-6, endothelin 1, retinol bind-
ing protein 4, leptin, adiponectin, and resistin) (data not
shown). Whereas statins have been shown to have a
beneficial effect on endothelial function and blood flow
within the macrovasculature (e.g., flow-mediated dilation),
our data with high-dose atorvastatin for 6 months showed
no effect of statin on any of the measured aspects of
muscle microvascular function. Fegan et al. (43) showed,
in individuals with type 2 diabetes, no improvement in
cutaneous vascular response after 3 months’ treatment
with single or combined lipid-lowering therapy. Although
no effect of 4 weeks’ treatment with 20 mg/day atorvastatin
was observed on vasomotor function by high-resolution
ultrasound examination of the brachial artery (flow-medi-
ated dilation and sublingual nitrate) (44), a beneficial
effect of statins on aspects of endothelial function has
been noted over 6 months (45). It is plausible that turnover
of endothelial cells or neovascularization is needed to
improve aspects of microvascular function as measured in
our study. Six months’ treatment with statins may be
insufficient time for this to occur. It is possible that our
failure to detect a difference in microvascular function
with statin treatment represents a type 2 statistical error.
However, our randomized placebo-controlled trial sample
size gave us 97% power to detect a 1.0-SD change in Kf at
FIG. 3. Kf, isovolumetric pressure (Pvi), and resting limb blood flow (Qa) measured before and after 26 weeks’ treatment with atorvastatin
(40 mg once daily) or matched placebo.
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the 5% significance level, and a 1.0-SD change in Kf
represents a1.1-unit change in Kf, or an increase in mean
Kf from 3.9 to 5.0  10
3 ml  min1  100 ml1  mmHg1.
Our study was therefore powered to detect relatively
modest changes in Kf, and more marked changes in Kf
have been observed with electrical stimulation and with
exercise. Electrical stimulation for 4 weeks increased Kf
from 3.38  0.38 to 6.68  0.62 (P  0.05) (24), and a
14-week training program during which lower limbs were
trained for endurance caused a 79% improvement in Kf
(from 2.4  0.8 to 4.3  0.9, P  0.05) (26,35–38). Thus,
these data suggest that our study was powered to detect
physiologically relevant changes in Kf.
The methods available to investigate muscle microvas-
culature are limited, and those used to measure the whole
tissue or insulin-mediated capillary perfusion and flow are
very invasive, for example, radiolabeled imaging tech-
niques (46), contrast enhanced ultrasound using albumin
microbubbles (9), needle-inserted laser Doppler probes
(8), or measurements of the distribution of blood flow by
[15O]H2O as an index of flow heterogeneity (47). One way
of assessing blood/muscle exchange, and hence to assess
impaired muscle microvascular function, is to quantify the
capacity of the microvascular bed to filter fluid. Plethys-
mography is a well-validated, noninvasive technique that
uses small-step increases in venous occlusion pressure
and measurement of the resultant changes in limb volume
to provide a measure of microvascular filtration capacity
(Kf) (48). Kf, which is measured predominantly in the
muscle of the lower limb, has been shown to be differen-
tially sensitive to increases in capillary surface area, as
found in training schedules (26), as well as sensitive
enough to detect increases in capillary perfusion, as in
studies involving chronic electrical stimulation (24). Kf
thus appears to be an important and sensitive measure to
detect impairment of microvascular function, and the
methodology used (plethysmography) does not affect the
function of the vasculature under study (17). In the current
study, a noninvasive measure was used that was accept-
able to subjects returning for testing at the end of the
study. We reasoned that the greater technical ease of the
Filtrass system and its good reproducibility, together with
its noninvasive nature, would result in better compliance
in our nonpaid volunteers who were required to return for
follow-up measurements at the end of the intensive
6-month clinical trial. Many of the techniques mentioned
above used to assess changes in blood flow in muscle rely
on visualization of erythrocyte movement or their partic-
ulate surrogates. Moreover, the movement of plasma,
which determines bulk transfer and microvascular surface
interchange of small solutes to sustain the optimal diffu-
sion gradient, cannot be readily visualized. Plethysmo-
graphic assessment of Kf goes some way toward
addressing this matter by measuring the rate of fluid
exchange across the whole muscle microvascular bed.
This enables evaluation of microvascular filtration param-
eters, by which significant differences due to pathophysi-
ology and/or therapeutic interventions can be studied.
Other more invasive techniques provide evidence of an
insulin-mediated microvascular “recruitment” in human
muscle through a selective action on precapillary arte-
rioles (9–11,13,49) to redirect blood to “nutritive” vascular
beds. The measurement of Kf or Qa by plethysmography
does not allow us to distinguish between variations in
muscle blood flow due to shifts, or redistribution, within
microvascular networks and those in total blood flow, as
determined by the resistance vessels supplying the mus-
cle. It is possible that variation in muscle blood flow due
to shifts, or redistribution, within microvascular net-
works could explain some of the wide variance in
microvascular measurements (Fig. 1) that we observed
across our cohort.
In summary, we have shown a strong association be-
tween skeletal muscle Kf and decreased insulin sensitivity
in skeletal muscle in men and women with central obesity.
Despite marked decreases in LDL cholesterol and hsCRP
concentrations caused by 6 months’ high-dose statin treat-
ment, there was no improvement in any measure of
skeletal muscle microvascular function, suggesting that
these factors do not make an important contribution to
control of microvascular function. Our data emphasize
that further studies are now required to investigate the
effects of insulin-sensitizing agents on microvascular func-
tion both in individuals at risk of type 2 diabetes and in
those who have type 2 diabetes.
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